19:29 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma; solid tumors Inhibiting CDK7 could treat hedgehog signaling-driven cancers resistant to SMO inhibitors. A CDK7 inhibitor tool compound decreased viability of cells resistant to SMO inhibitors and driven...
01:17 , Jun 29, 2019 |  BC Extra  |  Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
21:26 , Nov 21, 2018 |  BC Extra  |  Company News

Management tracks: BerGenBio, Alzamend

BerGenBio ASA (OSE:BGBIO) said Clinical Development Officer Murray Yule will step down on Nov. 30. The cancer company hired former Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) leader Alan Barge as interim CMO. Barge...
20:07 , Oct 11, 2018 |  BC Extra  |  Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

Going big in Europe

Arch Venture's biggest investment to date in Europe is also the complete opposite of how the firm normally starts biotech companies. Arch is co-leading a tranched $95 million series A round for Carrick Therapeutics Ltd....
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

Carrick completes venture financing

Carrick Therapeutics Ltd. , Dublin, Ireland   Business: Cancer   Date completed: 2016-10-03   Type: Venture financing   Raised: $95 million   Investors: Arch Venture Partners; Woodford Investment Management; Cambridge Enterprise; Cambridge Innovation Capital; Evotec...
07:00 , Oct 3, 2016 |  BC Extra  |  Financial News

Carrick raises $95M for cancer programs

Newco Carrick Therapeutics Ltd. (Dublin, Ireland) debuted with $95 million in a venture round led by Arch Venture Partners and Woodford Investment Management. Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG (Xetra:EVT), GV and...